Ruth Riisnaes

10.0k total citations
42 papers, 1.5k citations indexed

About

Ruth Riisnaes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ruth Riisnaes has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Ruth Riisnaes's work include Prostate Cancer Treatment and Research (19 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cancer Genomics and Diagnostics (7 papers). Ruth Riisnaes is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cancer Genomics and Diagnostics (7 papers). Ruth Riisnaes collaborates with scholars based in United Kingdom, United States and Spain. Ruth Riisnaes's co-authors include Johann S. de Bono, Timothy A. Yap, Lorna Pope, David Olmos, Adekemi Taylor, George Thomas, Daniel M. Sullivan, Lisa Lupinacci, Simon P. Heaton and Daniel Nava Rodrigues and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ruth Riisnaes

40 papers receiving 1.4k citations

Peers

Countries citing papers authored by Ruth Riisnaes

Since Specialization

Citations

This map shows the geographic impact of Ruth Riisnaes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Riisnaes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Riisnaes more than expected).

Fields of papers citing papers by Ruth Riisnaes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Riisnaes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Riisnaes. The network helps show where Ruth Riisnaes may publish in the future.

Co-authorship network of co-authors of Ruth Riisnaes

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Riisnaes. A scholar is included among the top collaborators of Ruth Riisnaes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Riisnaes. Ruth Riisnaes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	84 Deciphering the immune microenvironment in castration-resistant prostate cancer (CRPC) through hyperplex immunofluorescence and AI-assisted image analysis: Unveiling potential immunotherapy biomarkers 2023 ·SHILAP Revista de lepidopterología ·Bora Gürel, Ines Figueiredo, Mateus Crespo, Christina Guo, George Seed, Ana Ferreira, Ruth Riisnaes, Wei Yuan, Suzanne Carreira, Johann S. de Bono	1
2	Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma 2023 ·JAMA Oncology ·Susana Banerjee, Gaia Giannone, Andrew R. Clamp, Darren Ennis, Rosalind Glasspool, (unknown), Jonathan Krell, Ruth Riisnaes, Hasan Mirza, (unknown), Jacqueline McDermott, Clare Green, Rebecca Kristeleit, Angela George, Charlie Gourley, Liz-Anne Lewsley, (unknown), Udai Banerji, Samantha Hinsley, Iain A. McNeish	13
3	Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer 2023 ·Laboratory Investigation ·Antje Neeb, Ines Figueiredo, Bora Gürel, Daniel Nava Rodrigues, Jan Rekowski, Ruth Riisnaes, (unknown), Susana Miranda, Mateus Crespo, Daniel Westaby, Maria D. Fenor de la Maza, Christina Guo, Juliet Carmichael, (unknown), Nina Tunariu, Andrew C.B. Cato, Stephen R. Plymate, Johann S. de Bono, Adam Sharp	0
4	Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer 2023 ·European Urology Open Science ·(unknown), Suzanne Carreira, Susana Miranda, Ines Figueiredo, Cláudia Bertan, Jan Rekowski, Wei Yuan, Ana Ferreira, Ruth Riisnaes, Antje Neeb, Bora Gürel, Maria D. Fenor de la Maza, Christina Guo, Juliet Carmichael, Daniel Westaby, Joaquı́n Mateo, Adam Sharp, Terri McVeigh, Johann S. de Bono	5
5	Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer 2022 ·Clinical Cancer Research ·Beshara Sheehan, Antje Neeb, Lorenzo Buroni, Alec Paschalis, Ruth Riisnaes, Bora Gürel, Veronica Gil, Susana Miranda, Mateus Crespo, Christina Guo, (unknown), Ines Figueiredo, Ana Ferreira, Jon Welti, Wei Yuan, Suzanne Carreira, Adam Sharp, Johann S. de Bono	22
6	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation – a Single Unit Experience 2021 ·Cancer Treatment and Research Communications ·Andrea Biondo, Abhijit Pal, Ruth Riisnaes, (unknown), (unknown), (unknown), (unknown), Cláudia Bertan, Mateus Crespo, Ana Ferreira, Rita Pereira, Ines Figueiredo, Susana Miranda, Bora Gürel, Suzanne Carreira, Udai Banerji, Johann S. de Bono, Juanita Lopez, Nina Tunariu, Anna Minchom	2
7	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer 2019 ·Clinical Cancer Research ·Susan F. Slovin, Syed A. Hussain, Fred Saad, Jorge García, Joel Picus, Roberta Ferraldeschi, Mateus Crespo, Penelope Flohr, Ruth Riisnaes, Chih‐Che Lin, Harold Keer, Aram Oganesian, Paul Workman, Johann S. de Bono	31
8	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss 2018 ·Clinical Cancer Research ·Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, Christophe Massard, Sergio Bracarda, Albert Font, Jóse Ángel Arranz Arija, Kent C. Shih, George Daniel Rădăvoi, Na Xu, Wai Yee Chan, Han Ma, Steven Gendreau, Ruth Riisnaes, Premal H. Patel, Daniel Maslyar, Viorel Jinga	227
9	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer 2018 ·Clinical Cancer Research ·Daniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, Mateus Crespo, Susana Miranda, Pasquale Rescigno, Ines Figueiredo, Ruth Riisnaes, Suzanne Carreira, Semini Sumanasuriya, Paola Gasperini, Adam Sharp, Joaquı́n Mateo, (unknown), Christopher McNair, Matthew J. Schiewer, Karen E. Knudsen, Gunther Boysen, Francesca Demichelis, Johann S. de Bono	44
10	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status 2017 ·Annals of Oncology ·Anuradha Jayaram, Karolina Nowakowska, Joaquı́n Mateo, Tomás Martín Hernández, Sandeep Kumar, (unknown), Daniel Nava Rodrigues, Ruth Riisnaes, A. Zukiwski, Stefan Proniuk, Alice Bexon, (unknown), Diletta Bianchini, Zafeiris Zafeiriou, (unknown), Nina Tunariu, Simon Pacey, Rhys D.O. Jones, Johann S. de Bono, G. Attard	3
11	PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) 2016 ·Annals of Oncology ·Johann S. de Bono, Ugo De Giorgi, Christophe Massard, Sergio Bracarda, Daniel Nava Rodrigues, Ivo Kocák, Albert Font, (unknown), Kent C. Shih, George Daniel Rădăvoi, (unknown), Wen‐Ching Chan, Steven Gendreau, (unknown), Ruth Riisnaes, Matthew Wongchenko, Daniel Maslyar, Viorel Jinga	40
12	Myeloid-derived suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients (PTS) 2016 ·Annals of Oncology ·Niven Mehra, George Seed, Maryou Lambros, Adam Sharp, Mariane Fontes, Mateus Crespo, Semini Sumanasuriya, Wei Yuan, Gunther Boysen, Ruth Riisnaes, Arianna Calcinotto, Suzanne Carreira, Jane Goodall, Zafeiris Zafeiriou, Diletta Bianchini, Alison Morilla, Ricardo Morilla, Andrea Alimonti, Johann S. de Bono	6
13	Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. 2016 ·Journal of Clinical Oncology ·Brent O’Carrigan, Maria J. de Miguel, D. Papadatos-Pastos, Jessica Brown, Nina Tunariu, (unknown), (unknown), Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Brian Hare, Fang Yang, K. Mcdermott, Marina S. Penney, John R. Pollard, Juanita Lopez, Udai Banerji, Johann S. de Bono, Scott Z. Fields, Timothy A. Yap	28
14	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents 2015 ·British Journal of Cancer ·Mateus Crespo, Guus van Dalum, Roberta Ferraldeschi, Zafeiris Zafeiriou, Spyridon Sideris, David Lorente, Diletta Bianchini, Daniel Nava Rodrigues, Ruth Riisnaes, Susana Miranda, I. Figueiredo, Penelope Flohr, Karolina Nowakowska, Johann S. de Bono, Leon W.M.M. Terstappen, Gerhardt Attard	53
15	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort. 2015 ·Journal of Clinical Oncology ·Anuradha Jayaram, Karolina Nowakowska, Joaquı́n Mateo, Daniel Nava Rodrigues, Ruth Riisnaes, Alexander Zukiwski, Stefan Proniuk, Alice Bexon, (unknown), Diletta Bianchini, Zafeiris Zafeiriou, (unknown), Nina Tunariu, Johann S. de Bono, Gerhardt Attard	1
16	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer 2014 ·Clinical Cancer Research ·Sarah P. Blagden, (unknown), Debra H. Josephs, Chara Stavraka, Andrea Zivi, David J. Pinato, Alan Anthoney, Shaun Decordova, Karen E. Swales, Ruth Riisnaes, Lorna Pope, Kohei Noguchi, (unknown), (unknown), (unknown), Keith Jones, Chris Twelves, James Spicer, Udai Banerji	36
17	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer 2013 ·British Journal of Cancer ·Diletta Bianchini, Aurelius Omlin, Carmel Pezaro, David Lorente, Roberta Ferraldeschi, Deborah Mukherji, Mateus Crespo, I. Figueiredo, Susana Miranda, Ruth Riisnaes, Andrea Zivi, Aby Buchbinder, Dana E. Rathkopf, Gerhardt Attard, Howard I. Scher, Johann S. de Bono, Daniel C. Danila	72
18	Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging (NCT009794131). 2013 ·Journal of Clinical Oncology ·Khurum Khan, Anna-Mary Young, Joaquı́n Mateo, Nina Tunariu, Timothy A. Yap, David S.P. Tan, David Mansfield, Mabel Wong, Ruth Riisnaes, Kevin J. Harrington, Johann S. de Bono	5
19	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer 2012 ·Modern Pathology ·Alison Reid, Gerhardt Attard, Daniel Brewer, Susana Miranda, Ruth Riisnaes, Jeremy Clark, (unknown), Sue Merson, Roy Vergis, Charles Jameson, S. Høyer, (unknown), Michael Borre, Chris Jones, Johann S. de Bono, Colin S. Cooper	35
20	Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers 2012 ·PLoS ONE ·Géraldine Perkins, Timothy A. Yap, Lorna Pope, Amy Mulick, Juliet Dukes, Ruth Riisnaes, Christophe Massard, Philippe A. Cassier, Susana Miranda, Jeremy Clark, (unknown), Khin Thway, David González de Castro, Gerhardt Attard, L Rhoda Molife, Stan B. Kaye, Udai Banerji, Johann S. de Bono	126

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact